Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1Hodgkin Disease 1Colorectal Neoplasms 1

Interventions

pembrolizumab 44Specimen Handling 44Biopsy 36Magnetic Resonance Spectroscopy 34Carboplatin 24Paclitaxel 23Nivolumab 20Gemcitabine 20Irinotecan 18Radiosurgery 16Cisplatin 14Pemetrexed 13Taxes 11Ipilimumab 11Fluorouracil 11Cetuximab 11trastuzumab deruxtecan 10olaparib 10Leucovorin 10130-nm albumin-bound paclitaxel 10abemaciclib 9Oxaliplatin 9Cyclophosphamide 9Capecitabine 9Bevacizumab 9palbociclib 8durvalumab 8Trastuzumab 8Fulvestrant 8ribociclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Immunohistochemistry × 90 days × Clear all
NCT06311214 2026-05-27

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
500 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡